Celltrion Group Chairman Seo Jung-jin said that after the merger between the Celltrion Group's three major affiliates is completed, he may look into an initial public offering (IPO) process for Celltrion Holdings controlling Celltrion, Celltrion Healthcare, and Celltrion Pharm.

Speaking to about 3,200 investors during an online Q&A session on Thursday, Seo shared plans for the merger of the three core Celltrion Group affiliates - Celltrion, Celltrion Healthcare, and Celltrion Pharm - and answered investor questions directly.

When asked by an investor whether the company executives have plans to buy additional stocks to boost stock prices, Chairman Seo mentioned the possibility of an IPO for Celltrion Holdings.

"We will first complete the merger process, and after that, we will consider listing Celltrion Holdings," Seo said. "If there's a surplus from the IPO, we will increase our stake in the company."

Seo also promised that neither Celltrion Holdings nor he will sell its shares for profit.

Investors expressed concerns about the sluggish stock prices of Celltrion and Celltrion Healthcare, despite the company announcing merger plans for the two companies on Sep. 17 after market close.

While the shares of the two companies rose on Sep. 18, it has since given back all its gains.

Celltrion's closing price on Friday was 143,500 won ($108), which is not much different from the closing price of 143,600 won on Sep. 17.

Meanwhile, Celltrion Group is in the process of merging its three affiliates. Under the first phase, Celltrion will acquire Celltrion Healthcare. The companies plan to finalize the merger process within the year, followed by the merger of Celltrion Pharmaceuticals within six months.

If Celltrion absorbs and merges Celltrion Healthcare as planned, Celltrion Holdings and Seo will hold a 21.5 percent and 3.7 percent stake in the combined entity, and the combined entity will hold a 54.8 percent stake in Celltrion Pharm.